Thermo Fisher and Juno sign seven-year CAR-T tech deal

By Flora Southey contact

- Last updated on GMT

GettyImages/7activestudio
GettyImages/7activestudio
Juno Therapeutics will use Thermo Fisher Scientific’s Cell Therapy Systems (CTS) technology to develop CAR T therapies for cancer treatments.

The agreement will see Thermo Fisher supply Juno with CTS Dynabeads CD3/CD28 for seven years in a nonexclusive licensing deal.

Thermo Fisher said the magnetic beads – which it makes at its manufacturing facility in Vilnius, Lithuania – activate and expand T cells specially designed to identify and combat cancer cells in patients. 

“Thermo Fisher’s Dynabeads T cell expansion bead platform is already proven in commercial manufacturing, and is known for greater stability and scalability, which are critical requirements for CAR T manufacturers,” ​Thermo Fisher COO Mark Stevenson told us.

According to Stevenson, the firms have worked together since Juno was founded in 2013.

“Today’s announcement formalises the relationship to allow maximum collaboration to bring product to patients,” ​he said.

Financial details of the deal were not disclosed.

Thermo Fisher also supplies​ its CTS Dynabeads technology for CAR-T immunotherapies to Swiss firm Novartis.

The US Food and Drug Administration (FDA) approved​ Novartis’ CAR-T immunotherapy Kymriah (tisagenlecleucel) in August last year, making it the first commercially available CAR-T treatment in the US.

Related news

Related products

The Next Stage – Eppendorfs new Mastercycler X50

The Next Stage – Eppendorfs new Mastercycler X50

Eppendorf for Bioprocess – Solutions that grow with you | 05-Sep-2017 | Application Note

The Mastercycler X50 is Eppendorf's new PCR cycler with lots of new benefits. Not only can you heat with 10°C/s, you can also optimize two different...

Related suppliers